Jane’s practice focuses primarily on health care enforcement defense. Jane defends laboratories, physicians, and other clients facing government investigations and qui tam litigation arising from alleged violations of the federal False Claims Act (FCA), the Stark Law, and alleged criminal and civil violations of the anti-kickback statute. Jane assists clients with negotiation and structuring of global settlements with the US Department of Justice and its US Attorneys’ Offices and state Attorneys' General Offices as well as corporate integrity agreements with the Department of Health and Human Services Office of Inspector General. Jane also defends clients in consumer protection and unfair or deceptive trade practices investigations initiated by the Federal Trade Commission or state Attorneys’ General Offices. Jane also advises clients regarding cannabis licensing, compliance, and regulatory matters.
Recent victories to which Jane has contributed include:
- Successfully defended a national laboratory against a whistleblower’s qui tam complaint.
- Defense verdicts on summary judgment in multi-jurisdictional product liability disputes involving FDA-approved pharmaceutical drugs and assay test development.
- Defense verdict on partial summary judgment in a bet-the-company case involving a dispute between the majority owner of a multi-billion dollar company and private equity investors.
Jane also maintains an active pro bono practice, succeeding on an appeal before an administrative law judge and securing social security benefits for her client. Jane has also appeared in family and probate court on behalf of her clients in guardianship and custody matters. Most recently, Jane’s pro bono practice has focused on social justice efforts, including participating in CORI sealing clinics and conducting research specific to assisting individuals with criminal records in understanding their public housing options. Jane also participates in the Lawyers Clearinghouse Legal Clinic for the Homeless, through which Mintz attorneys provide legal representation to residents of Boston-area homeless shelters.
While attending law school at night and working full time for the State Auditor’s Office, Jane was the winner of the National Moot Court New England Regional Competition and the two-time winner of the Tom C. Clark Appellate Advocacy Competition. She also served as Comment Editor of the Suffolk University Law Review. She graduated first in her class from Suffolk Law’s evening program.
viewpoints
CMS Proposed Rule for Refunding Overpayments Would Align With False Claims Act “Knowledge” Standard
January 17, 2023 | Blog | By Laurence Freedman, Jane Haviland
The Centers for Medicare & Medicaid Services (CMS) proposed a rule late last year to harmonize the standard it would apply for providers to identify and refund overpayments with the “knowledge” standard under the False Claims Act (FCA) and the Civil Monetary Penalties Law. Though this proposal purportedly ensures that a lack of “reasonable diligence” cannot create civil liability, it would create significant confusion as to how CMS expects providers and Medicare Advantage organizations (MAOs) to “identify” and quantify potential overpayments before triggering the 60-day period to refund them. The proposed rule, if adopted, would likely become part of the framework for the Department of Justice and Department of Health & Human Services’ Office of Inspector General when evaluating potential liability for the alleged failure to return overpayments.
Mintz Health Law: What We Are Grateful For
January 11, 2023 | Podcast | By Bridgette Keller
Bridgette Keller speaks with the Mintz Health Law team about what they are grateful for as they look back on a year of client service, mentorship, and working together as a team.
Serial Relator Brings Multiple Lawsuits Alleging False Claims Act Violations Premised on Paycheck Protection Program Fraud
November 2, 2022 | Blog | By Laurence Freedman, Jane Haviland
This blog highlights a recently unsealed qui tam case brought by relator GNGH2, Inc against 15 entities that allegedly operated nursing homes in the Bronx, New York and in Florida and various health care staffing agencies.
California Attorney General Probes Bias in Health Care Algorithms
September 12, 2022 | Blog | By Lara Compton, Jane Haviland
A spurt of letters from California Attorney General, Rob Bonta, to leaders of hospitals and other health care facilities sent on August 31, 2022 signaled the kickoff of a government probe into bias in health care algorithms that contribute to material health care decisions. This blog post highlights the California Office of the Attorney General’s initiative to address disparities in health care and what this probe may mean for the use algorithms and AI in health care.
Two Recent False Claims Act Settlements Highlight the Benefits of Self-Disclosure, Remediation, and Cooperation
July 19, 2022 | Blog | By Karen Lovitch , Lauren Moldawer, Jane Haviland
Disclosing known or suspected fraud to regulators can have its benefits. As reported in a previous post, the Department of Justice (DOJ) issued policy guidance in 2019 on providing credit in False Claims Act (FCA) settlements to corporations for “disclosure, cooperation, and remediation” (the Policy Guidance). Since then, the industry has been watching to see how DOJ implements this Policy Guidance.
Two settlements announced earlier this month seem to demonstrate that DOJ is applying the Policy Guidance in resolving FCA cases. Although the facts of these two settlements differ significantly, they highlight the benefits of self-disclosure, cooperation with the government in its investigation, and proactive efforts to remediate non-compliance.
FDA Expresses Displeasure with Consumer Products Containing Trendy Cannabis Ingredient Delta-8 THC
May 13, 2022 | Blog | By Jane Haviland, Joanne Hawana
On May 4, 2022, the U.S. Food and Drug Administration (FDA) for the first time issued warning letters related to products containing delta-8 tetrahydrocannabinol (delta-8 THC). FDA has previously sent warning letters to other companies illegally selling unapproved and misbranded cannabidiol, or CBD, products that claimed to treat illness in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act), as we have discussed in prior posts (one example here). In a separate recent slew of CBD-related actions, it issued warning letters jointly with the Federal Trade Commission (FTC) to seven companies for selling CBD products with claims that they will treat or prevent COVID-19. This blog post will define delta-8 THC and analyze the FDA's warning letters.
Health Care Enforcement Year in Review & 2022 Outlook
February 11, 2022 |
False Claims Act Settlements and Judgments Exceed $5.6 Billion in Fiscal Year 2021
February 2, 2022 | Blog | By Laurence Freedman, Jane Haviland
Removing Barriers to Second Chances
January 24, 2022 | Article
Nurturing a Community-Based Approach to Food Access
January 18, 2022 | Article
News & Press
Cannabis Ruling Lights Path For Bankruptcy Protection
April 16, 2024
Ruling Casts Shadow On Cannabis Employees' Ch. 13 Relief
February 16, 2023
Associates Jane Haviland, Kathryn Droumbakis, and Rachel Sposato co-authored an article published by Law360 discussing bankruptcy relief for employees in the cannabis industry.
Events & Speaking
Healthcare Regulatory Considerations for Patient Incentives: AKS and CMPL Compliance, Safe Harbors, Exceptions
Strafford CLE
Virtual Webinar
Enforcement and Data Analytics
ABA 32nd Annual National Institute on Health Care Fraud
Caesars Palace
Publications
- Co-author, Crackdown on COVID-19 Testing Fraud Continues, Published by G2 Intelligence (2024)